RB202

RB202 is a preclinical-stage drug candidate being developed by Rarefied Biosciences for the treatment of autoimmune diseases. It represents the company's second program, following their lead candidate RB201, which is an oral inhibitor that has completed Phase 1 trials. Rarefied Biosciences focuses on developing first-in-class oral therapies that 're-tune' the immune system by targeting upstream drivers of immune activation to restore balance without causing broad immunosuppression. As of early 2024, RB202 is in the discovery phase, and specific details regarding its molecular target, chemical modality, and precise mechanism of action have not been publicly disclosed.